← Eichor
Condition: Pulmonary Tuberculoses Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pulmonary Tuberculoses

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
Phase N/A · 1 location(s) · University of Oxford · NCT06845618ATORvastatin in Pulmonary TUBerculosis
Phase 2 · 8 location(s) · Obafemi Awolowo University Teaching Hospital · NCT06199921A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
Phase 3 · 2 location(s) · Shanghai Jiatan Pharmatech Co., Ltd · NCT05824871Treatment Monitoring for NTM Infections With a Symptom Diary
Phase N/A · 3 location(s) · Research Center Borstel · NCT07131774Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Phase 2 · 29 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06192160LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea
Phase N/A · 1 location(s) · Yonsei University · NCT06946784Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
Phase 2 · 1 location(s) · Thirty Respiratory Limited · NCT07073638A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
Phase 2 · 7 location(s) · WestVac Biopharma Co., Ltd. · NCT07170800Mediastinal EBUS Cryobiopsy Study In Sweden
Phase N/A · 2 location(s) · Region Skane · NCT06347939Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Phase N/A · 3 location(s) · University of Oxford · NCT06526689Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
Phase 2 · 13 location(s) · Gates Medical Research Institute · NCT07525427Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
Phase 2 · 11 location(s) · Global Alliance for TB Drug Development · NCT07672405A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
NA · 1 location(s) · The Aurum Institute NPC · NCT06909799Pragmatic Optimized Rifampicin Trial
Phase 3 · 2 location(s) · Radboud University Medical Center · NCT06057519Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Phase 4 · 6 location(s) · Bin Cao · NCT07213765Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
Phase N/A · 1 location(s) · University College, London · NCT07192705Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Phase N/A · 2 location(s) · Peking University Third Hospital · NCT05426720Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susc
Phase 2 · 4 location(s) · Gates Medical Research Institute · NCT07517445Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fib
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06602869A PAN-USR TB Multi-Center Trial
Phase 3 · 3 location(s) · Shenzhen Third People's Hospital · NCT06905522Seoul National University Airway Registry
Phase N/A · 3 location(s) · Seoul National University Hospital · NCT02527486Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
Phase N/A · 1 location(s) · ChromX Health · NCT0652841818F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07077213Remimazolam for Bronchoscopy in High-Risk Patients
Phase 4 · 2 location(s) · First Affiliated Hospital of Zhejiang University · NCT07395596Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
Phase 4 · 1 location(s) · Beijing Chest Hospital · NCT06403943ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
Phase 1 · 4 location(s) · Quratis Inc. · NCT06714513Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
Phase N/A · 2 location(s) · Karolinska Institutet · NCT06585358A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
Phase 2 · 1 location(s) · TASK Applied Science · NCT06748937
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.